Advertisement

Topics

ABLYNX INITIATES THE PHASE IIb "RESPIRE" STUDY OF ITS WHOLLY-OWNED, FIRST-IN-CLASS, INHALED ANTI-RSV NANOBODY, ALX-0171, FOR THE TREATMENT OF RSV INFECTIONS IN HOSPITALISED INFANTS

12:45 EST 11 Jan 2017 | GlobalNewsWire (2014)
This article has expired, however you can still download the PDF.
Preview:
ALX-0171 is a first-in-class inhaled Nanobody® developed for the treatment of RSV infections ALX-0171 was safe and well tolerated in a Phase IIa study in hospitalised infants with a RSV infection ALX-0171 had an immediate and signific...

Other Sources for this Article

NEXT ARTICLE

More From BioPortfolio on "ABLYNX INITIATES THE PHASE IIb "RESPIRE" STUDY OF ITS WHOLLY-OWNED, FIRST-IN-CLASS, INHALED ANTI-RSV NANOBODY, ALX-0171, FOR THE TREATMENT OF RSV INFECTIONS IN HOSPITALISED INFANTS"

Quick Search
Advertisement
 

Relevant Topics

Infectious-diseases
Antiretroviral Therapy Clostridium Difficile Ebola HIV & AIDS Infectious Diseases Influenza Malaria Measles Sepsis Swine Flu Tropical Medicine Tuberculosis Infectious diseases are caused by pathogenic...

Drug Discovery
Clinical Approvals Clinical Trials Drug Approvals Drug Delivery Drug Discovery Generics Drugs Prescription Drugs In the fields of medicine, biotechnology and pharmacology, drug discovery is the process by which drugs are dis...